Clinical trial · Observational
Asia Study Group of Prostate Cancer (A-CaP Study)
Research Concerning Background Factors at Time of Diagnosis and Initial Treatment and Treatment Progress Cancer Patients in Asia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will target patients who have received a histopathological diagnosis of prostate cancer and who are undergoing treatment in various forms, including active PSA surveillance, surgical treatment, radiotherapy, endocrine therapy, and chemotherapy. The study will survey information about the patient at time of diagnosis, clinical staging, details of initial treatment, status of disease progression, and prognosis at the end point of the study. The purpose of the study is to clarify distribution of staging, the actual status of treatment choices and treatment outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Prostate Cancer
- description
- About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
Primary outcomes (1)
- measure
- Patients background at time of diagnosis of prostate cancer, treatment progress and prognosis with the reason for progression and subsequent treatment methods
- timeFrame
- three years
- description
- The following items are examined for primary outcome measure. 1. Patient background which is represented by month and year of birth; height and weight; ethnicity and family history; medical history; and name of condition/disease for which currently receiving treatment at hospital. 2. Information pertaining to prostate cancer which is represented by PSA value at time of prostate cancer diagnosis and Gleason score. 3. Prognosis information which is survival or death at end point of the Study.
Secondary outcomes (1)
- measure
- Patient QOL measured by SF-36 during treatment by comparison with A-Cap data and data in the United States and Australia
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Patients who have received a histopathological diagnosis of prostate cancer between January 1,2016,and December 31,2018. * Patients who, having received a diagnosis within the abovementioned period, began initial treatment for prostate cancer(including active surveillance). * Patients who are either hospitalized as outpatients. Exclusion Criteria: • Patients for whom information about the time of diagnosis, including histopathological diagnosis, cannot be acquired.
References
Publications (2)
- BACKGROUNDOnozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Akaza H. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan. Jpn J Clin Oncol. 2014 Oct;44(10):969-81. doi: 10.1093/jjco/hyu104. Epub 2014 Aug 6. PMID 25098707
- BACKGROUNDCooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol. 2009 Sep 10;27(26):4306-13. doi: 10.1200/JCO.2008.21.5228. Epub 2009 Aug 10. PMID 19667269